Asfotase alfa - Biologic Drug Details

Summary for asfotase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for asfotase alfa

Recent Clinical Trials for asfotase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Alexion Pharmaceuticals, Inc.	Phase 4
Alexion Pharmaceuticals, Inc.	Phase 3
Alexion Pharmaceuticals	Phase 4

See all asfotase alfa clinical trials

Pharmacology for asfotase alfa

Established Pharmacologic Class	Tissue-nonspecific Alkaline Phosphatase
Chemical Structure	Alkaline Phosphatase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for asfotase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for asfotase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2036-09-07	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2035-08-27	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2037-03-27	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2036-02-12	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2038-12-10	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2036-03-22	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2036-12-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for asfotase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2036-01-28	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2035-07-10	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2037-08-18	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2037-03-31	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513		2032-10-25	Patent claims search

International Patents for asfotase alfa

Country	Patent Number	Estimated Expiration
European Patent Office	2300493
South Korea	20180088919
World Intellectual Property Organization (WIPO)	2016148402
World Intellectual Property Organization (WIPO)	2010039924
World Intellectual Property Organization (WIPO)	2011130249
Israel	195525
World Intellectual Property Organization (WIPO)	2016150964

Asfotase alfa Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Asfotase Alfa?

Asfotase alfa, marketed as Strensiq by Alexion Pharmaceuticals (a part of AstraZeneca since 2021), targets hypophosphatasia (HPP), a rare genetic disorder impairing bone mineralization. Its market environment is shaped by disease prevalence, regulatory status, competitive landscape, and reimbursement policies.

Disease Prevalence and Market Potential

Hypophosphatasia (HPP) affects approximately 1 in 100,000 to 200,000 individuals globally, with more cases detected through gene sequencing. The ultra-rare nature restricts the total addressable market. However, the disease's severity—leading to skeletal abnormalities, respiratory failure, and metabolic disturbances—generates a high unmet medical need, promoting regulatory incentives.

Regulatory Pathways and Approvals

Initially approved by the FDA in 2015 for pediatric-onset HPP, Strensiq received expanded approval in 2017 for adults. The European Medicines Agency (EMA) approved it in 2016. The approval process entailed orphan drug designation, incentivizing market entry but limiting market size.

Reimbursement and Market Access

Reimbursement depends on health technology assessments. High treatment costs—annual costs exceeding $300,000 in the U.S.—pose access barriers in some regions. Countries with established orphan drug pathways and favorable pricing policies demonstrate higher utilization.

Competitive Landscape

The market effectively has no direct biologic competitors, owing to HPP’s rarity and the unique enzyme replacement mechanism of asfotase alfa. Analogous growth in gene therapy and novel enzyme-based approaches remains a future risk.

Distribution and Prescriber Base

Primarily managed by metabolic specialists and pediatric endocrinologists, the patient pool in specialized centers influences distribution channels. As awareness grows, prescriber numbers may increase.

How Is the Financial Trajectory of Asfotase Alfa Evolving?

Financial data for Strensiq reveal strong initial sales, with steady growth aligned with expanded indications and geographic penetration. Since its launch, the drug has generated significant revenue for Alexion/AstraZeneca.

Revenue and Sales Growth

In 2020, AstraZeneca reported Strensiq sales of approximately $200 million, up from $150 million in 2019. Sales growth sustained through new markets and broader reimbursement coverage. The COVID-19 pandemic temporarily affected healthcare utilization but did not significantly reduce overall sales.

Revenue Breakdown by Region

• North America: 60%
• Europe: 25%
• Other markets (Asia, Middle East): 15%

North American markets remain dominant due to higher diagnosis rates and established specialty centers.

Cost Structure

Development and manufacturing costs are significant, given the complex biologic production process. Cost of goods sold (COGS) approximates 30-40% of sales, with marketing and sales expenses constituting about 15%.

Profitability and Outlook

Historically, Strensiq contributed positively to AstraZeneca’s revenue within its rare diseases portfolio. The potential for off-label use or broader indications remains limited, constraining explosive growth.

Future Revenue Drivers

• Expanded approvals for adult HPP
• Increased diagnosis rates via genetic testing
• Launch in emerging markets with improved access

Risks to Financial Trajectory

• Pricing pressures and reimbursement restrictions
• Competition from gene therapy options
• Manufacturing scalability issues affecting supply

What Are the Key Market and Financial Risks?

The market for asfotase alfa remains confined by the rarity of HPP and limited diagnosis rates. Pricing pressures and reimbursement hurdles in some regions could constrain revenue growth. The advent of gene therapies and other innovative treatments targeting bone metabolic disorders could threaten the current monopoly.

Manufacturing complexity and the high cost of biologic production pose operational risks. Supply chain disruptions may impact availability and sales.

Key Takeaways

• The global hypophosphatasia market is small but stable, driven primarily by regulatory incentives and high treatment costs.
• Sales growth is currently moderate; long-term potential hinges on broader diagnosis and expanded indications.
• Profitability is supported by high pricing, but external pressures like reimbursement and competition could dampen margins.
• Future growth depends on geographic expansion, improved diagnosis, and advances in gene therapy.
• Manufacturing capacity and supply chain resilience are critical operational considerations.

FAQs

1. What is the current market size for asfotase alfa?
Estimated annual global sales approximate $200–$250 million, driven mainly by North America and Europe.

2. Is there a potential for new competitors in the HPP biologic market?
Yes. The development of gene therapies or alternative enzyme replacements could eventually challenge asfotase alfa’s market dominance.

3. How do pricing and reimbursement policies influence revenue?
High treatment costs require favorable reimbursement arrangements, which vary by country, affecting patient access and sales.

4. Can asfotase alfa's sales grow beyond current levels?
Limited by the small patient population; growth depends on increased diagnosis, geographic expansion, and potential new indications.

5. What operational risks could impact future financial performance?
Supply chain disruptions, manufacturing scaling challenges, and regulatory hurdles in new markets pose risks.

---

References

[1] AstraZeneca Annual Report 2021.
[2] FDA Approval Announcement for Strensiq. (2015)
[3] EMA Product Information for Strensiq. (2016)
[4] Global Data, Rare Disease Market Reports, 2022.